8-K: Annovis Bio Announces Positive Alzheimer's Data and Provides Corporate Update

Annovis Bio reported positive Phase II/III Alzheimer's data and provided a corporate update, including financial results for the first quarter of 2024.

Summary

• Annovis Bio announced statistically significant positive results from its Phase II/III study in early Alzheimer's disease, showing a 3.3 point improvement in cognition as measured by ADAS-Cog 11 at three months compared to 0.3 for placebo.
• The company plans to conduct an 18-month pivotal Phase III trial in biomarker-positive early Alzheimer's patients based on these findings.
• The Phase III Parkinson's disease trial data unblinded on May 9, 2024, with topline results expected in June 2024.
• The company filed a patent application for buntanetap to treat neuropsychiatric indications.
• Annovis Bio's cash and cash equivalents totaled $3.1 million as of March 31, 2024, and they estimate that current funds will support operations into the fourth quarter of 2024.
• Total operating expenses for the first quarter of 2024 were $7.8 million, compared to $10.0 million for the same period in 2023.
• The company reported a basic net loss per common share of $0.10 and a diluted net loss per common share of $0.72 for the first quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial results for Alzheimer's, but the low cash position and delay in Parkinson's data temper the overall sentiment. The company is making progress but faces financial challenges.

Positives

• The Phase II/III Alzheimer's study showed a significant improvement in cognitive function.
• The reduction in plasma Tau protein levels supports the drug's mechanism of action.
• The company is moving forward with a pivotal Phase III trial for Alzheimer's.
• Operating expenses have decreased year-over-year.
• The company has filed a new patent application expanding the potential use of buntanetap.

Negatives

• The company's cash position has decreased from $5.8 million to $3.1 million in the quarter.
• The company reported a net loss per share for the quarter.
• The Parkinson's Phase III data release was delayed due to data cleaning efforts.

Risks

• The company's cash position is low, and they will need to raise additional capital to fund operations beyond the fourth quarter of 2024.
• The success of the Phase III trials is not guaranteed, and results may not be positive.
• There are risks associated with patient enrollment, the effectiveness of Buntanetap, and the timing of clinical trials.
• The company is subject to risks and uncertainties detailed in their SEC filings.

Future Outlook

The company anticipates that current cash reserves, combined with the $0.8 million from the ELOC Purchase Agreement, will fund operations into the fourth quarter of 2024. They also plan to conduct a pivotal 18-month Phase III trial for Alzheimer's and release topline results for the Parkinson's Phase III trial in June 2024.

Management Comments

• The first quarter proved to be pivotal for our company as we continued to wind down our two recent clinical trials Phase III in Parkinsons and Phase II/III in Alzheimers.
• For our PD study, which concluded late last year, diligent efforts are underway to meticulously prepare the data, with expected delivery of topline results in June of this year.
• For the AD study, we successfully cleaned the data and were proud to announce cognitive improvements as measured by ADAS-Cog 11 in patients with early AD, showing us a pathway for continued clinical development of buntanetap.
• We extend our heartfelt gratitude to the patients and their families whose contribution was the driving force of our research aimed to bring new treatments to the market.

Industry Context

This announcement is significant in the context of the neurodegenerative disease treatment landscape, where there is a high unmet need for effective therapies for Alzheimer's and Parkinson's. The positive results from the Alzheimer's trial and the upcoming Parkinson's results could position Annovis Bio as a key player in this space.

Comparison to Industry Standards

• The 3.3 point improvement in ADAS-Cog 11 scores in the Annovis Bio study is notable when compared to other Alzheimer's treatments in development, such as Lecanemab (Leqembi) which showed a 0.45 point improvement at 18 months in a similar patient population.
• The reduction in plasma Tau protein levels is also a positive indicator, as many other treatments focus on amyloid plaques, and this suggests a different mechanism of action.
• The company's approach of targeting multiple neurotoxic proteins is different from many other companies that focus on a single target, such as Biogen and Eisai with their amyloid-targeting drugs.
• The company's cash position is a concern, as many biotech companies with similar clinical programs have significantly more cash on hand, such as Cassava Sciences which has over $170 million in cash.

Stakeholder Impact

• Shareholders may react positively to the positive Alzheimer's data, but the low cash position could cause concern.
• Patients and their families may be encouraged by the progress in Alzheimer's treatment.
• Employees may be impacted by the company's financial situation and future funding needs.

Next Steps

• Annovis plans to conduct a pivotal 18-month disease-modifying Phase III trial in biomarker-positive early AD patients.
• The company intends to release topline results from the Phase III Parkinson's disease trial in June of 2024.

Key Dates

Keywords

Alzheimer's disease, Parkinson's disease, buntanetap, neurodegenerative diseases, clinical trials, Phase III, Phase II/III, ADAS-Cog 11, biomarkers, cognitive improvement, neuropsychiatric, patent, financial results